KPV (Lysine-Proline-Valine) is a synthetic tripeptide derived from the C-terminal terminus of alpha-melanocyte-stimulating hormone (α-MSH). Investigated extensively for its capacity to down-regulate inflammatory signal transduction pathways without stimulating melanogenesis, high-purity KPV vials serve as crucial reference materials for in vitro and preclinical models of mucosal homeostasis.
KPV (Lysine-Proline-Valine) is a synthetic tripeptide derived from the C-terminal terminus of alpha-melanocyte-stimulating hormone (α-MSH). Investigated extensively for its capacity to down-regulate inflammatory signal transduction pathways without stimulating melanogenesis, high-purity KPV vials serve as crucial reference materials for in vitro and preclinical models of mucosal homeostasis.
A KPV vial contains a vacuum-sealed, lyophilized powder of Lysine-Proline-Valine, a tripeptide fragment corresponding to amino acids 11–13 of the endogenous peptide hormone alpha-melanocyte-stimulating hormone (α-MSH). Formulated specifically for laboratory research use, KPV is evaluated in cell culture and animal models to investigate targeted anti-inflammatory signaling, cellular peptide transport, and epithelial barrier stabilization without triggering pigmentary responses.
Researchers evaluating a KPV vial rely on its high chemical stability and low molecular weight to probe nuclear factor kappa B (NF-κB) pathways. Unlike its parent molecule α-MSH, KPV lacks the amino acid sequence required for melanocortin 1 receptor (MC1R) activation related to pigmentation, allowing investigators to isolate inflammatory cascades from pigmentary downstream effects in preclinical experiments available across the broader PX1 Research catalog.
KPV is a tripeptide composed of L-lysine, L-proline, and L-valine connected via standard peptide bonds, resulting in a low molecular weight of approximately 341.45 g/mol. Its chemical simplicity offers unique pharmacokinetic advantages in experimental designs, including rapid cellular uptake and systemic diffusion in animal models.
Because of its small size and specific sequence motif, KPV interacts efficiently with oligopeptide transporters, specifically PepT1 (SLC15A1). In vitro studies indicate that PepT1 facilitates the intracellular trans-epithelial transport of KPV, enabling the peptide to act directly within the cytoplasm to interact with intracellular signaling complexes without requiring classical G-protein coupled receptor (GPCR) surface binding.
The primary mechanism of action documented for KPV in preclinical literature centers on the inhibition of nuclear factor kappa B (NF-κB) activation. NF-κB is a master transcription factor governing the expression of pro-inflammatory cytokines, chemokines, and cell adhesion molecules. In vitro cell assays demonstrate that KPV entry into the cell results in the suppression of IκBα phosphorylation and subsequent translocation of the NF-κB p65 subunit into the nucleus.
By inhibiting NF-κB activation, KPV leads to a measurable reduction in the transcript levels of inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Furthermore, preclinical models evaluating inducible nitric oxide synthase (iNOS) demonstrate that KPV administration correlates with reduced nitric oxide production in stimulated macrophages, highlighting its broad utility in cellular inflammatory research.
A substantial portion of KPV literature focuses on mucosal tissue dynamics, particularly within gastrointestinal disease models. In animal models of dextran sulfate sodium (DSS)-induced colitis, researchers observe that KPV administration significantly attenuates histologic inflammation, reduces crypt damage, and preserves mucosal architecture.
In vitro models utilizing Caco-2 cell monolayers show that KPV helps preserve epithelial barrier integrity under inflammatory stress. Preclinical data indicate that KPV upregulates or maintains the expression of key tight junction proteins—such as Zonula Occludens-1 (ZO-1) and occludin—thereby mitigating inflammatory-induced hyperpermeability. These findings make KPV a standard reference agent in studies exploring leaky gut mechanisms and inflammatory bowel pathophysiology.
When designing preclinical protocols for tissue repair and inflammation, researchers often compare KPV against other established laboratory compounds. While KPV acts primarily via PepT1-mediated intracellular NF-κB suppression, BPC-157 operates through distinct growth factor expression pathways and nitric oxide system modulation. Meanwhile, Larazotide Acetate targets tight junction assembly antagonizing zonulin pathways directly, and LL-37 functions as an antimicrobial host defense peptide with broad immunomodulatory properties.
Unlike larger proteins or complex peptides, KPV's minimal tripeptide structure offers exceptional chemical stability and low immunogenicity in culture media. The table below outlines key experimental parameters across these comparative compounds:
Proper reconstitution of a lyophilized KPV vial is critical to maintaining peptide integrity and obtaining reproducible analytical data. Lyophilized KPV is readily soluble in standard laboratory aqueous solutions, including sterile bacteriostatic water, phosphate-buffered saline (PBS, pH 7.4), and standard cell culture media.
To reconstitute, scientists typically allow the vial to equilibrate to room temperature before adding the desired volume of sterile diluent along the inner glass wall. Swirl the vial gently; avoid vigorous vortexing or shaking, which can induce physical shear stress and aggregation. Stock solutions intended for long-term cell culture work should be filtered through a 0.22-micron low-protein-binding syringe filter under a laminar flow hood to maintain sterility.
Lyophilized KPV powder exhibits high physical stability when stored under proper environmental controls. For long-term preservation (up to 24 months), sealed vials must be stored at -20°C or -80°C in a desiccated environment to prevent moisture contamination and hydrolytic degradation.
Once reconstituted into aqueous solution, KPV stock solutions should be divided into single-use aliquots to prevent repeated freeze-thaw cycles, which degrade peptide purity over time. Aliquoted liquid solutions remain stable at 4°C for up to 7 to 14 days, or at -20°C for up to 3 to 6 months. Detailed storage protocols and analytical benchmarks are available through the PX1 Research Hub.
When performing quantitative assays, researchers require absolute purity verification to avoid confounding experimental outcomes. Inferior research peptides contaminated with residual synthesis reagents, TFA salts, or endotoxins can alter cellular responses and produce invalid assay results.
Every lot of KPV provided by PX1 Research undergoes rigorous testing in an ISO 17025 accredited laboratory. Purity is validated via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a baseline purity exceeding 98%. Molecular weight identity is confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS). Crucially, Chromogenic Limulus Amebocyte Lysate (LAL) testing is conducted to verify endotoxin levels remain strictly under 0.01 EU/mg, preventing background immune cell activation during sensitive in vitro assays.
PX1 Research is a dedicated USA-based supplier of high-purity research compounds for academic institutions, biotechnology firms, and contract research organizations. All peptides are manufactured under strict GMP-compliant guidelines within US facilities, ensuring consistent batch-to-batch reproducibility.
Orders ship same-day (Monday through Friday) directly from our distribution hubs in California and Arizona. Every shipment includes a lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms and mass spectra. Institutional buyers and lab managers seeking bulk quantities or custom specifications can access tailored procurement options through our PX1 Wholesale Portal.
What is the primary sequence and molecular weight of KPV?
KPV is a tripeptide with the amino acid sequence Lysine-Proline-Valine (Lys-Pro-Val). It has a molecular weight of approximately 341.45 g/mol.
How does KPV differ from full-length alpha-MSH in preclinical research?
Full-length α-MSH activates melanocortin receptors (MC1R through MC5R), triggering pigmentary and metabolic pathways alongside anti-inflammatory signaling. KPV represents only the C-terminal tripeptide fragment; it retains anti-inflammatory activity via PepT1 transport and NF-κB inhibition without stimulating MC1R or melanogenesis.
What diluents are recommended for reconstituting a KPV vial?
For in vitro and cell culture applications, KPV is typically reconstituted in sterile phosphate-buffered saline (PBS, pH 7.4) or sterile bacteriostatic water. Ensure proper aseptic technique during handling.
Why is low endotoxin content critical for KPV research?
Endotoxins (lipopolysaccharides) independently activate NF-κB and Toll-like receptor 4 (TLR4) pathways in immune and epithelial cells. If a KPV sample contains endotoxin contamination, it can mask or alter the tripeptide's true inhibitory effects on cellular inflammatory models.
How should reconstituted KPV stock solutions be stored?
Reconstituted liquid KPV should be aliquoted into small, single-use volumes to prevent freeze-thaw degradation. Liquid aliquots are stable at 4°C for up to 14 days and at -20°C for up to 6 months.
Does PX1 Research provide lot-specific COAs with KPV vials?
Yes. Every KPV vial supplied by PX1 Research includes a lot-specific Certificate of Analysis featuring third-party RP-HPLC purity verification (>98%), mass spectrometry mass confirmation, and LAL endotoxin testing data.
Is KPV suitable for human administration or clinical use?
No. KPV vials supplied by PX1 Research are strictly designated for laboratory research use only. They are not intended for human or animal consumption, medical treatment, diagnosis, or clinical applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.